• Channels
    • All News
    • In Focus
    • Special
    • AI
    • Bioregnum
    • Biotech Voices
    • Cell/Gene Tx
    • China
    • Coronavirus
    • Deals
    • Diagnostics
    • Discovery
    • FDA+
    • Financing
    • Health Tech
    • Law
    • Letters to the Editor
    • Manufacturing
    • Marketing
    • Nikkei Biotechnology
    • Opinion
    • Outsourcing
    • Peer Review
    • People
    • Pharma
    • R&D
    • Startups
    • Weekly
  • Webinars
  • Biopharma Jobs
  • More
    • Work at Endpoints
    • Letter to Editors
    • Editorial Standards
    • IPO Tracker
    • Webinars
    • Events
    • Sponsored Posts
    • Advertise
    • Privacy Policy
    • Endpoints Merch
    • About Us
    • Help
  • SIGN UP
  • LOG IN

Back­lash: Har­vard ex­perts fret over the fall­out from FDA’s OK for Sarep­ta’s con­tro­ver­sial Duchenne drug

9 years ago
R&D

Chi­na: Fraud not the on­ly rea­son 1,193 drug ap­pli­ca­tions were with­drawn; Ad­vax­is shares drop

9 years ago
News Briefing

In­ovio shares slide af­ter FDA hits it with a hold on lead PhI­II HPV pro­gram

9 years ago
R&D

New Lis­te­ria fears spot­light­ed as Aduro’s CRS-207 is slapped with par­tial hold

9 years ago
R&D

Shire bids CTI and its trou­bled myelofi­bro­sis drug adieu, buy­ing its way out of a deal

9 years ago
R&D

Ze­ro­ing in on Mer­ck ri­val, GSK steps up to the FDA with its top new vac­cine prospect

9 years ago
R&D

Mer­ck com­pletes a clin­i­cal tri­al Odyssey, fi­nal­ly bag­ging an FDA OK for C diff an­ti­body

9 years ago
R&D

Let's re­think Clin­ton's war on phar­ma; The FDA can't or­der the ge­nie back in­to the mag­ic lamp

9 years ago
Bioregnum
Opinion

Porges to Bio­gen: I don’t like your neu­ro­path­ic pain drug; Ex-Mod­er­na ex­ec Bolen joins PureTech as CSO

9 years ago
News Briefing

Cere­cor’s $1M Lil­ly deal put it in the right place at the right time to­day

9 years ago
R&D

Roche ad­justs Avastin fran­chise de­fense plans as PhII suc­ces­sor fails a key study

9 years ago
R&D

Hot on the heels of its Bris­tol-My­ers slap­down, Mer­ck scores PhI­II blad­der can­cer suc­cess with Keytru­da

9 years ago
R&D

Alk­er­mes plots course to the FDA af­ter its de­pres­sion drug scores suc­cess in last-stand PhI­II

9 years ago
R&D

Gilead needs a big R&D hit. Here's why claims on NASH fall well short of that

9 years ago
R&D

In­vestors add $17M to Em­u­late Se­ries B as Co­v­ance part­ners; UMass pro­fes­sor to work with Spark on next-gen vec­tors

9 years ago
News Briefing

Backed by neu­ro en­thu­si­ast Arch, up­start Black­Thorn tack­les some tough tar­gets with $40M round

9 years ago
R&D

Rigel’s 2nd PhI­II for fos­ta­ma­tinib scut­tled by a sin­gle place­bo re­sponse, shares crater

9 years ago
R&D

No sur­prise: Ab­b­Vie turns cold shoul­der to a messy rheuma­toid arthri­tis part­ner­ship with Abl­ynx

9 years ago
R&D

Eli Lil­ly wins a quick OK for new sar­co­ma drug olara­tum­ab

9 years ago
R&D

Now that Sarep­ta has bolt­ed out of the barn, the FDA wants to shut the door

9 years ago
Bioregnum
R&D

Liv­er tox cas­es force Dai­ichi Sankyo to cur­tail re­cruit­ment for PhI­II tri­al of a ‘break­through’ drug

9 years ago
R&D

No­var­tis throws Cerulean a life­line with $5M deal; Porges diss­es Cel­gene’s GED-0301

9 years ago
News Briefing

Can­cer pow­er­house Roche el­bows its way in­to a check­point show­down with Bris­tol-My­ers, Mer­ck

9 years ago
R&D

Ox­ford spin­out Arg­onaut looks to hack can­cer cells and pro­gram them to die

9 years ago
R&D
First page Previous page 1158115911601161116211631164 Next page Last page
Endpoints News

Bioscience & Technology Business Center
The University of Kansas
Lawrence, Kansas

Latest

  • All News
  • Special
  • In Focus

Channels

  • AI
  • Bioregnum
  • Biotech Voices
  • Cell/Gene Tx
  • China
  • Coronavirus
  • Deals
  • Diagnostics
  • Discovery
  • FDA+
  • Financing
  • Health Tech
  • Law
  • Letters to the Editor
  • Manufacturing
  • Marketing
  • Nikkei Biotechnology
  • Opinion
  • Outsourcing
  • Peer Review
  • People
  • Pharma
  • R&D
  • Startups
  • Weekly

More

  • Work at Endpoints
  • Letter to Editors
  • Editorial Standards
  • IPO Tracker
  • Events
  • Webinars
  • Sponsored Posts
  • Advertise
  • Endpoints Merch
  • About Us
  • Help

Work in biotech

  • Endpoints Careers

© Endpoints News 2025

  • Help
  • Advertise
  • Privacy Policy
  • Business Model
FT Specialist Logo
A service from the Financial Times
Endpoints News

Confirm Profile

Endpoints News